HPV prevalence, E6 sequence variation and physical state of HPV16 isolates from patients with cervical cancer in Sichuan, China

Gynecologic Oncology

Volumn 104, Issue 1, 2007, Pages 77-85

  Qiu, Ai Dong ^a   Wu, En Qi ^a   Yu, Xiang Hui ^a   Jiang, Chun Lai ^a   Jin, Ying Hua ^a   Wu, Yong Ge ^a   Chen, Yue ^a   Chen, Yan ^a   Shan, Ya Ming ^a   Zhang, Guo Nan ^b   Fan, Ying ^b   Zha, Xiao ^b   Kong, Wei ^a  

^a JILIN UNIVERSITY   (China)

^b SICHUAN CANCER HOSPITAL   (China)

Author keywords

E6 variation; Human papillomavirus; Physical state; Prevalence

Indexed keywords

GLYCOPROTEIN E2; PROTEIN E6; VIRUS DNA; VIRUS GLYCOPROTEIN;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; EPISOME; FEMALE; GENE DISRUPTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; INFECTION RISK; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEIC ACID BASE SUBSTITUTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS GENE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN; WART VIRUS;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHINA; DNA, VIRAL; DNA-BINDING PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS; VIRUS INTEGRATION;

EID: 33846029866     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.07.016     Document Type: Article

References (50)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol. 2 9 (2001 (Sep)) 533-543
2. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus DNA in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 87 11 (1995 (Jun 7)) 796-802
3. Stewart A.C., Eriksson A.M., Manos M.M., Munoz N., Bosch F.X., Peto J., et al. Intratype variation in 12 human papillomavirus types: a worldwide perspective. J. Virol. 70 5 (1996 (May)) 3127-3136
4. Lo K.W., Wong Y.F., Chan M.K., Li J.C., Poon J.S., Wang V.W., et al. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int. J. Cancer 100 3 (2002 (Jul 20)) 327-331
5. Xiao X., Cao M., Miller T.R., Cao Z.Y., and Yen T.S. Papillomavirus DNA in cervical carcinoma specimens from central China. Lancet 2 8616 (1988 (Oct 15)) 902
6. Peng H.Q., Liu S.L., Mann V., Rohan T., and Rawls W. Human papillomavirus types 16 and 33, herpes simplex virus type 2 and other risk factors for cervical cancer in Sichuan province China. Int. J. Cancer 47 5 (1991 (Mar 12)) 711-716
7. Stephen A.L., Thompson C.H., Tattersall M.H., Cossart Y.E., and Rose B.R. Analysis of mutations in the URR and E6/E7 oncogenes of HPV 16 cervical cancer isolates from central China. Int. J. Cancer 86 5 (2000 (Jun 1)) 695-701
8. Zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184 1 (1991 (Sep)) 9-13
9. Xi L.F., Demers G.W., Koutsky L.A., Kiviat N.B., Kuypers J., Watts D.H., et al. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J. Infect. Dis. 172 3 (1995 (Sep)) 747-755
10. Alvarez-Salas L.M., Wilczynski P., Burger R.A., Monk B.J., and Dipaolo J.A. Polymorphism of the HPV-16 E6 gene of cervical carcinoma. Int. J. Oncol. 7 3 (1995 (May)) 261-266
11. Zehbe I., Wilander E., Delius H., and Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 58 4 (1998 (Feb 15)) 829-833
12. Daniel B., Rangarajan A., Mukherjee G., Vallikad E., and Krishna S. The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions. J. Gen. Virol. 78 5 (1997 (May)) 1095-1101
13. Cullen A.P., Reid R., Campion M., and Lorincz A.T. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J. Virol. 65 2 (1991 (Feb)) 606-612
14. Durst M., Kleinheinz A., Hotz M., and Gissmann L. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumors. J. Gen. Virol. 66 7 (1985 (Jul)) 1515-1522
15. Jeon S., and Lambert P.F. Integration of HPV-16 DNA into the human genome leads to increased stability of E6/E7 mRNAs: implications for cervical carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 92 5 (1995 (Feb 28)) 1654-1658
16. Bernard B.A., Bailly C., Lenoir M.C., Darmon M., Thierry F., and Yaniv M. The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV18 regulatory region in human keratinocytes. J. Virol. 63 10 (1989 (Oct)) 4317-4324
17. Romanczuk H., Thierry F., and Howley P.M. Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 P97 and type 18 P105 promoters. J. Virol. 64 6 (1990 (Jun)) 2849-2859
18. Scheffner M., Huibregtse J.M., Viestra R.D., and Howley P.M. The HPV16 E6 and E6-AP complex functions as a ubiquitin protein ligase in the ubiquitination of p53. J. Cell 75 3 (1993 (Nov 5)) 495-505
19. Wheeler C.M., Yamada T., Hildesheim A., and Janison S.A. Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization. J. Clin. Microbiol. 35 1 (1997 (Jan)) 11-19
20. Tonon S.A., Picconi M.A., Bos P.D., Zinovich J.B., Galuppo J., Alonio L.V., et al. Physical status of the E2 human papillomavirus 16 viral gene in cervical preneoplastic and neoplastic lesions. J. Clin. Virol. 21 2 (2001 (May)) 129-134
21. Lukaszuk K., Liss J., Wozniak I., Emerich J., and Wojcikowski C. Human papillomavirus type 16 status in cervical carcinoma cell DNA assayed by multiplex PCR. J. Clin. Microbiol. 41 2 (2003 (Feb)) 608-612
22. Kleter B., van Doorn L.J., ter Schegget J., Schrauwen L., Van Krimpen K., Burger M., et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am. J. Pathol. 153 6 (1998 (Dec)) 1731-1739
23. Chichareaon S., Herrero R., Munoz N., Bosch F.X., Jacobs M.V., Deacon J., et al. Risk factors for cervical cancer in Thailand: a case-control study. J. Natl. Cancer Inst. 90 1 (1998 (Jan 7)) 50-57
24. Ferenczy A., and Franco E. Cervical-cancer screening beyond the year 2000. Lancet Oncol. 2 1 (2001 (Jan)) 27-32
25. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, vol. 64, Human Papillomaviruses, pp. 47-52. Lyon: International Agency for Research on Cancer, World Health Organization. IARC (1995).
26. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 1 (1999 (Sep)) 12-19
27. Huano S., Afonina I., Miller B.A., and Beckmann A.M. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int. J. Cancer 70 4 (1997 (Feb)) 408-411
28. Durst M., Gissman L., Ikenberg H., and Zur HauSen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. U. S. A. 80 12 (1983 (Jun)) 3812-3815
29. Meanwell C.A., Cox M.F., Blackledge G., and Maitland N.J. Hpv16 in normal and malignant cervical epithelium: implications for the aetiology and behavior of cervical neoplasia. Lancet 1 8535 (1987 (Mar 28)) 703-707
30. Crook T., Wrede D., Tidy J.A., Mason W.P., Evans D.J., and Vousdan K.H. Clonal P53 mutation in primary cervical cancer: association with human papillomavirus-negative tumors. Lancet 339 8801 (1992 (May 2)) 1070-1073
31. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88 1 (2003 (Jan 13)) 63-73
32. Pham T.H., Nguyen T.H., Herrero R., Vaccarella S., Smith J.S., Nguyen Thuy T.T., et al. Human papillomavirus infection among women in South and North Vietnam. Int. J. Cancer 104 2 (2003 (Mar 20)) 213-220
33. Gonzalez-Losa Mdel R., Rosado-Lopez I., Valdez-Gonzalez N., and Puerto-Solis M. High prevalence of human papillomavirus type 58 in Mexican colposcopy patients. J. Clin. Virol. 29 3 (2004 (Mar)) 202-205
34. Chan P.K., Li W.H., Chan M.Y., Ma W.L., Cheng J.L., and Cheng A.F. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J. Med. Virol. 59 2 (1999 (Oct)) 232-238
35. Jie L., Bao-yin L., and Hausen Z. Investigation of the infection and geographical distribution of HPV in cervical carcinoma tissues from Chinese women. Chinese Journal of Experimental and Clinical Virology 10 1 (1996) 50-55
36. Duensing S., and Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 62 23 (2002 (Dec 1)) 7075-7082
37. Hubbard R.A. Human papillomavirus testing methods. Arch. Pathol. Lab. Med. 127 8 (2003 (Aug)) 940-945
38. Ewen M.E., Sluss H.K., Sherr C.J., Matsushime H., Kato J., and Livingston D.M. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73 3 (1993 (May 7)) 487-497
39. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., and Klingelhutz A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396 6706 (1998 (Nov 5)) 84-88
40. Nindl I., Rindfleisch K., Lotz B., Schneider A., and Durst M. Uniform distribution of Hpv 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int. J. Cancer 82 2 (1999 (Jul 19)) 203-207
41. Yamada T., Manos M., Peto J., Greer C.E., Munoz N., Bosch F.X., et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J. Virol. 71 3 (1997 (Mar)) 2463-2472
42. Hu X., Guo Z., Tianyun P., Ponten F., Wilander E., Andersson S., et al. Hpv typing and hpv16 E6-sequence variations in synchronous lesions of cervical squamous-cell carcinoma from Swedish patients. Int. J. Cancer 83 1 (1999 (Sep 24)) 34-37
43. Kast W.M., Brandt R.M., Sidney J., Drijfhout J.W., Kubo R.T., Grey H.M., et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 152 8 (1994 (Apr 15)) 3904-3912
44. Lechner M.S., Mack D.H., Finicle A.B., Crook T., Vousden K.H., and Laimins L.A. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11 8 (1992 (Aug)) 3045-3052
45. Nakagawa S., Watanabe S., Yoshikawa H., Taketani Y., Yoshiike K., and Kanda T. Mutation analysis of human papllomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology 212 (1995) 535-542
46. Klaes R., Woerner S.M., Ridder R., Wentzensen N., Duerst M., Schneider A., et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 59 24 (1999 (Dec 15)) 6132-6136
47. Daniel B., Mukherjee G., Seshadri L., Vallikad E., and Krishna S. Changes in the physical state and expression of human papillomavirus type 16 in the progression of cervical intraepithelial neoplasia lesions analysed by PCR. J. Gen. Virol. 76 10 (1995 (Oct)) 2589-2593
48. Pirami L., Giache V., and Becciolini A. Analysis of HPV 16, 18, 31 and 35 DNA in pre-invasive and invasive lesions of the uterine cervix. J. Clin. Pathol. 50 7 (1997 (Jul)) 600-6004
49. Chen C.M., Shyu M.P., Au L.C., Chu H.W., Cheng W.T., and Choo K.B. Analysis of deletion of the integrated human papillomavirus 16 sequence in cervical cancer: a rapid multiplex polymerase chain reaction approach. J. Med. Virol. 44 2 (1994 (Oct)) 206-211
50. Yoshinouchi M., Hongo A., Nakamura K., Kodama J., Itoh S., Sakai H., et al. Analysis by multiplex PCR of the physical status of human papillomavirus type 16 DNA in cervical cancers. J. Clin. Microbiol. 37 11 (1999 (Nov)) 3514-3517